Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07005362 · ClinicalTrials.gov registry record

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

A clinical trial of Type 2 Diabetes and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Colorado, Denver.

Recruiting
Registry status
36
Enrollment target
1
Study location

NCT07005362: Recruiting study of Type 2 Diabetes and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Colorado, Denver.

NCT07005362 is a study of Type 2 Diabetes and Type 2 Diabetes Mellitus (T2DM) that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 36 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07005362, a study of Type 2 Diabetes and Type 2 Diabetes Mellitus (T2DM), is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to evaluate the feasibility and acceptability of a 12-week intervention utilizing a Fitbit and artificial intelligence (AI)-delivered diabetes self-management education and support (DSMES) with tailored text messages. The main question it aims to answer is: Does providing a wearable fitness and activity tracker plus AI-tailored and DSMES improve clinical outcomes for patients with type 2 diabetes? Participants will complete a baseline visit, wear a Fitbit and answer text messages for 12-weeks, and complete by a final visit.

Primary Outcome

Recruitment of 36 adults within 6 months.

Conditions Studied

Type 2 Diabetes Type 2 Diabetes Mellitus (T2DM) T2DM (Type 2 Diabetes Mellitus) T2D Remote Patient Monitoring T2DM Artificial Intelegence

Interventions

  • BEHAVIORAL Fitbit and AI Chatbot
  • OTHER Routine Care

Study Locations (1)

Colorado

  • University of Colorado, Anschutz - Aurora

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-09-03
Est. Completion 2026-04-30
University of Colorado, Denver

1,283 total trials

What NCT07005362 shows while recruiting

NCT07005362 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).

The record links to 7 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Fitbit and AI Chatbot is the first listed.

NCT07005362 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT07005362 about?

NCT07005362 is a clinical study titled "Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D". The goal of this observational study is to evaluate the feasibility and acceptability of a 12-week intervention utilizing a Fitbit and artificial intelligence (AI)-delivered diabetes self-management education and support (DSMES) with tailored text messages. The main question it aims to answer is: ...

What is the current status of trial NCT07005362?

This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-09-03. Estimated completion is 2026-04-30.

What conditions does trial NCT07005362 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), T2DM (Type 2 Diabetes Mellitus), T2D, Remote Patient Monitoring.

What interventions are being tested in trial NCT07005362?

The interventions under investigation include: Fitbit and AI Chatbot (BEHAVIORAL), Routine Care (OTHER).

Who is sponsoring clinical trial NCT07005362?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07005362 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07005362's enrollment target sits among peer trials

36 243rd of 327 higher than 83 of 327 other Type 2 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07005362

Source: ClinicalTrials.gov NCT07005362, the US trial registry maintained by the National Library of Medicine. NCT07005362 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.